Dutch regulator rejects affordable cancer drug from NKI/KWF

The Dutch healthcare regulator has rejected a cancer medicine developed by the Netherlands Cancer Institute (NKI) and KWF, a major funding body. The rejection likely concerns cost-effectiveness or clinical evidence, impacting patient access and the institute's commercial prospects. This is a notable setback for an academic-led drug development initiative.